In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis

European Journal of Ophthalmology

Volumn 19, Issue 5, 2009, Pages 708-716

  Iovieno, Alfonso ^a   Lambiase, Alessandro ^a   Micera, Alessandra ^a,b   Stampachiacchiere, Barbara ^a,b   Sgrulleta, Roberto ^a   Bonini, Stefano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Chronic blepharitis; Doxycycline; Impression cytology; MMP 9; Tears; TIMP 1

Indexed keywords

DOXYCYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL ARTICLE; CYTOLOGY; DRUG ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FACE ERYTHEMA; FEMALE; GENE ACTIVATION; GENE INACTIVATION; HUMAN; IN VIVO STUDY; KERATOPATHY; LACRIMAL FLUID; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; ZYMOGRAPHY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; BLEPHARITIS; CHRONIC DISEASE; DOXYCYCLINE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TEARS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; UP-REGULATION;

EID: 70549085965     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900504     Document Type: Article

References (43)

1. Ayliffe W. Blepharitis and meibomian gland dysfunction. In: Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005; 647-56.
2. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol 2008; 43: 170-9.
3. Pruzanski W, Stefanski E, Vadas P, McNamara TF, Ramamurthy N, Golub LM. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2. J Rheumatol 1998; 25: 1807-12.
4. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000; 41: 2544-57.
5. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006; 82: 588-96.
6. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003; 47: 3630-3.
7. Smith VA, Cook SD. Doxycycline-a role in ocular surface repair. Br J Ophthalmol 2004; 88: 619-25.
8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
9. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005; 87: 249-63.
10. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83.
11. Di Girolamo N, McCluskey P, Lloyd A, Coroneo MT, Wakefield D. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci 2000; 41: 671-9.
12. Kawashima Y, Saika S, Yamanaka O, Okada Y, Ohkawa K, Ohnishi Y. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res 1998; 17: 445-51.
13. Sack RA, Conradi L, Krumholz D, Beaton A, Sathe S, Morris C. Membrane array characterization of 80 chemokines, cytokines, and growth factors in open- and closed-eye tears: angiogenin and other defense system constituents. Invest Ophthalmol Vis Sci 2005; 46: 1228-38.
14. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002; 92: 12-8.
15. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
16. Lafleur MA, Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 2003; 5: 1-39.
17. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16: 558-64.
18. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002; 21: 1-14.
19. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol 2001; 132: 8-13.
20. Sakimoto T, Shoji J, Sawa M. Active form of gelatinases in tear fluid in patients with corneal ulcer or ocular burn. Jpn J Ophthalmol 2003; 47: 423-6.
21. Sakimoto T, Shoji J, Kanno H, Sawa M. Gelatinase expression in ocular surface disorders. Jpn J Ophthalmol 2004; 48: 17-22.
22. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999; 40: 2506-12.
23. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Oent Res 1998; 12: 114-8.
24. Lokeshwar BL, Seizer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993; 53: 4493-8.
25. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999; 878: 271-89.
26. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann NY Acad Sci 1994; 732: 140-51.
27. Li DQ, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pflugfelder SC. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001; 73: 449-59.
28. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 2000; 41: 1703-9.
29. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-86.
30. Pfaffl MW, Morgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
31. Wilcox RR. New Statistical Procedures for the Social Sciences: Modern Solution to Basic Problems. Hillsdale, NJ: Lawrence Erlbaum Associates, 1987; 316-20.
32. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802.
33. Van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database Syst Rev 2005; 3: CD003262.
34. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1 % in the treatment of rosacea. J Drugs Dermatol 2007; 6: 641-5.
35. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea 2007; 26: 42-6.
36. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol 2004; 15: 499-502.
37. Stone DU, Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 2004; 23: 106-9.
38. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991; 32: 2970-5.
39. Pisella PJ, Brignole F, Pebbasch G, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 2000; 107: 1841-9.
40. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006; 83: 526-35.
41. Górska R, Nedzi-Góra M. The effects of the initial treatment phase and of adjunctive low-dose doxycycline therapy on clinical parameters and MMP-8, MMP-9, and TIMP-1 levels in the saliva and peripheral blood of patients with chronic periodontitis. Arch Immunol Ther Exp (Warsz) 2006; 54: 419-26.
42. Määttä M, Kari O, Tervahartiala T, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea - treatment effect of oral doxycycline. Graefes Arch Clin Exp Ophthalmol 2006; 244: 957-62.
43. Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate. J Periodontol 2007; 78: 127-34.